30 September 2024
Quadrise
plc
("Quadrise", "QED", the "Company" and together with its
subsidiaries the "Group")
Final Results and Notice of
AGM
Quadrise (AIM:QED), the
supplier of MSAR® and bioMSAR™ emulsion technology
and fuels, providing innovative lower cost and cleaner alternatives
to fuel oil and biofuels,
is pleased to announce its audited final results
for the year ended 30 June 2024.
Operational Summary:
·
Marine - The signature of the
binding trial agreement between Quadrise, MSC Shipmanagement Ltd
("MSC") and Cargill NV ("Cargill") has been subject to delays,
however, the parties are collaborating positively to finalise as
soon as possible. Upon signature, installation and commissioning of
the Company's trial equipment at the MAC² terminal is planned in Q4
2024, ahead of fuel production and the Proof-of-Concept tests
commencing in early Q1 2025. The bioMSAR™ LONO trial is planned to
complete 6-8 months following the 2-month long Proof-of-Concept
tests of MSAR® and bioMSAR™. During the LONO trial the
parties intend to conclude a Commercial Supply Agreement and secure
bioMSAR™ bunker supply operations to the marine sector by Cargill
from MAC2 facilities in Antwerp and Bruges on a
permanent basis in anticipation of a successful trial
conclusion.
·
Morocco - Following the
successful industrial demonstration test at an OCP SA ("OCP")
industrial site in Morocco, a Commercial Framework Agreement was
signed with OCP in May 2024. Preparations for a 30-day commercial
trial at OCP's Jorf Lasfar site are now underway and in parallel
Quadrise has opened discussions with candidate suppliers for
long-term commercial MSAR® supply with a view to signing
term supply agreements following successful trial
completion.
·
Utah
- Following successful pilot
drilling in Q2 2024, oil production testing commenced in July 2024
managed by Valkor. Oil production from the first well was confirmed
in September 2024. Representative production barrels of heavy sweet
oil were prepared by Valkor in September, samples of which are
being shipped to Quadrise for analysis and formulation optimisation
testing at QRF. Commercial marketing of MSAR® to
commence once the samples have been tested. Valkor expect to drill
additional oil wells on site by 2024 year-end to increase oil
production to 500-800 barrels per day. Provided a minimum of US$15
million of project financing is successfully raised by Valkor,
Valkor will pay Quadrise US$1.0 million under the terms of the Site
License and Supply Agreement. A further US$0.5 million is then due
from Valkor upon delivery of an MSAR® Manufacturing Unit
to the project site in Utah. Valkor have confirmed to the Company
that they are confident about their efforts to secure the necessary
project financing to enable these activities.
·
bioMSAR™
- During the period, testing commenced on blends of bioMSAR™
incorporating 'B30' marine biofuel (a blend of 30% biodiesel and
70% fuel oil) which, combined with glycerine, reduces the fossil
fuel content of our emulsion blends, providing an additional
potential pathway to bioMSAR™ Zero. When compared to diesel, the
B30-based bioMSAR™ blends demonstrated over 38% well-to-wake
CO2 reductions, enhanced diesel engine efficiency of
3-7%, and reductions in NOx emissions of 43%-59% compared with
diesel fuel during testing. Testing is now underway on higher
concentrations of waste-based bio-oils with the intention to
produce our first prototypes of 'B100' bioMSAR™ Zero, a 100%
sustainable biofuel. Quadrise is therefore on track to being able
to demonstrate a commercial bioMSAR™ Zero product well ahead of the
Company's 2030 target.
Financial Summary:
· Loss after tax of £2.9m (2023: £3.1m), of which of £1.5m (2023: £1.7m) is
attributable to production and development costs
and £1.3m (2023: £1.3m) relates to administrative
and corporate expenses.
· Total assets of £6.7m as at 30 June 2024 (2023:
£5.3m).
· Cash balances as at 30 June 2024 of £3.0m (2023:
£1.3m).
· Cumulative tax losses of £64.7m (2023: £62.1m) potentially
available for set-off against any future profits.
Jason Miles, Chief Executive Officer of Quadrise,
commented:
"The Company entered the 2024-25 financial year with strong
momentum and is preparing to play its part in accelerating the
global transition away from fossil fuels.
Energy economics, environmental considerations, and emissions
regulations are increasingly driving the business case for
MSAR® and bioMSAR™ technology. With strong market
conditions, the Company is well-positioned to progress commercial
trials with industry majors and build on traction gained during the
period with new potential clients while advancing biofuel options
for bioMSAR™ production and net-zero solutions.
The pending agreement with MSC and Cargill will formally kick
off activities at the MAC² terminal during Q4 2024, to prepare for
fuel supply to the MSC vessel trial from Q1 2025 onward followed by
commercial supply upon success. Our team is also preparing to
complete the OCP commercial trial in Morocco in early Q4 and has
commenced discussions with candidate suppliers for long-term
commercial MSAR® supply upon success. Heavy sweet oil
from the Valkor projects in Utah has commenced production, with the
State of Utah approving Valkor's plans for future drilling.
Conclusion of the MSAR® site license and planned
equipment delivery to Valkor in Utah is therefore expected, pending
successful resolution of eagerly awaited project financing by
Valkor.
We
acknowledge that progress during the period has been slower than we
had previously anticipated, however the time for Quadrise
technology delivery is now and the team are focused on achieving
that goal."
Notice of Annual General Meeting
Quadrise also gives notice that the Company's Annual General Meeting
("AGM") will be held at 12 noon on 22 November 2024 at the Park
Plaza County Hall Hotel, 1 Addington Street, London, SE1
7RY.
For additional information, please
contact:
Quadrise Plc
|
|
+44 (0)20
7031 7321
|
Andy Morrison, Chairman
Jason Miles, Chief Executive
Officer
|
|
|
|
|
|
Nominated
Adviser
|
|
|
Cavendish Capital Markets Limited
|
|
+44 (0)20
7220 0500
|
Ben Jeynes
|
|
|
Katy Birkin
|
|
|
Joint
Brokers
Shore Capital Stockbrokers Limited
|
|
+44 (0)20
7408 4090
|
Toby Gibbs, Rachel Goldstein
(Corporate Advisory)
|
|
|
Fiona Conroy (Corporate
Broking)
|
|
|
|
|
|
VSA
Capital Limited
Andrew Raca (Corporate
Finance)
Andrew Monk (Corporate
Broking)
|
|
+44 (0)20
3005 5000
|
|
|
|
Public & Investor
Relations
|
|
|
Cutbill Jacoby
Andy Cutbill
Paul Brannon
|
|
+44
(0)7841 576000
+44
(0)7759 629406
|
|
About Quadrise
Quadrise is the supplier of
MSAR® and bioMSAR™ emulsion technology and fuels,
providing innovative lower cost and lower carbon alternatives to
fuel oil and biofuels in the global power generation, shipping,
industrial and refining industries.
Learn more:
www.quadrise.com
Certain of the information contained within this announcement
is deemed by the Company to constitute inside information as
stipulated under The Market Abuse Regulation (EU 596/2014)
pursuant to the Market Abuse (Amendment) (EU Exit) Regulations
2018. Upon the publication of this announcement via a Regulatory
Information Service ("RIS"), this inside information is now
considered to be in the public domain.
Chair's Statement
The 2023-24 financial year has been
one of incremental progress, with the Company in a stronger
position operationally and financially at year end than at the same
time last year. Events after year end are further strengthening the
Company's position, with the awaited signature of a collaboration
agreement with MSC and Cargill allowing sitework to commence for
the vessel trials. With drilling samples from Valkor having now
been prepared and trials in Morocco with OCP due to commence soon,
the Company has entered the 2024-25 financial year with strong
momentum and remains both eager and well placed to play its part in
the global transition away from fossil fuels.
The global commercial and regulatory
landscape has never been more favourable for the adoption of
Quadrise technology. This was especially evident at the December
2023 COP 28 climate conference in Dubai, which saw nearly 200
countries reach a landmark agreement to phase out fossil fuels.
This milestone is boosting global efforts to fast-track
decarbonisation technologies, as governments, companies, and
investors push to prevent the worst effects of climate
change.
The shipping sector is now at the
forefront of this transition, with shipping operators and their
customers leading the way. At COP 28, CEOs of major shipping
companies called for a deadline on the manufacture of newbuild
fossil fuel-powered vessels and urged the IMO to establish
regulations for green fuel adoption. Meanwhile, marine freight
buyers like Amazon, Philips, and Nike joined the Zero Emission
Maritime Buyers Alliance (ZEMBA) to promote zero-emission shipping.
In September 2023, ZEMBA launched a request for proposals, seeking
bids to transport 600,000 containers over three years on ships that
offer a 90% reduction in emissions compared to traditional fossil
fuels.
Quadrise technology focuses on the
affordable and progressive decarbonisation of shipping through the
replacement of heavy fuel oils. It enables production of
MSAR® and lower carbon bioMSAR™ fuels, which are lower
cost, cleaner, simpler and safer alternatives to heavy fuel oil and
currently available biofuels. This allows shipping companies to
meet their emissions targets whilst avoiding the need for new
vessels or expensive and time-consuming retrofits.
Quadrise continues to build its
profile within our target market sectors. Efforts to expand our
client network this year have resulted in several promising
opportunities arising with prospective commercial partners. As part
of these efforts, the Company launched its second Sustainability
Report in November 2023. This report provides an accessible
reference point for leaders and decision-makers in the shipping and
industrial sectors who are looking to decarbonise their businesses
practically and economically.
The Sustainability Report sets out
our firm ambition to develop a commercially competitive net-zero
carbon emission fuel, 'bioMSAR™ Zero', by replacing the hydrocarbon
element of bioMSAR™ fuel with zero-carbon or carbon-negative
substitutes. Our goal is to have this fuel market-ready by 2030 and
the development programme is already well underway with
formulations tested to date that reduce CO2 by up to 38%
on a 'well to wake' basis.
Whilst we look to develop new
opportunities, our near-term approach remains unchanged, with
continued focus on our key projects with MSC, Valkor and OCP. These
represent the most appropriate use of our financial and other
resources and provide the most material pathways to
commercialisation and profitability in line with the Company's core
strategy.
Our project portfolio has been
developed to address the Company's strategy of creating demand
points for our technology in key geographical locations, whilst
stimulating supply around these areas. This will enable marine
customers such as MSC to bunker our fuel worldwide and incentivise
production partners to produce MSAR® and bioMSAR™. Our
project with Valkor is directed towards the production of less
carbon-intensive and very low sulphur versions of MSAR®
and bioMSAR™ for marine and power customers in North America. Our
project with OCP in Morocco is intended to generate
MSAR® supply in the Mediterranean, whilst our
prospective projects in Southeast Asia and Central America
potentially provide further points of presence in those regions,
preparing ourselves for the scaling of our business to meet
demand.
In last year's final results, I
commented that the year had been one of "continued strategic and
operational progress, but without a breakthrough". The year ending
30 June 2024 may have been more of the same, with the clear promise
shown around the time of the April 2024 fundraise then severely
tested by project delays outside the direct control of the Company.
Planned activities will provide a clear validation of Quadrise
focus on the decarbonisation of shipping and enable us to plan in
earnest for profitability and scaling of the business. We are not
yet completely "in the clear", as trials still need to be
successfully navigated, but our technology is tested, and we are
confident of success.
As I have stated on occasions
before, our ambitions for the business are limited more by the
availability of financial and operational resources than by the
scale of the significant opportunities that Quadrise can address.
Subject to financial circumstances, we intend to explore and
advance complementary technologies to strengthen our
decarbonisation proposition to customers. This will increase the
Company's impact on sustainability and ensure that our products and
services are high on the list when potential clients are looking
for solutions to reduce emissions.
On behalf of the Board, I would like
to express my sincere appreciation to our loyal shareholders for
their support. We recognise that this has been another year of
frustration and slower than expected progress, but we are confident
your patience will be rewarded.
Financial Results
The consolidated after-tax loss for
the year to 30 June 2024 was £2.9m (2023: £3.1m), with the loss per
share for the year reducing to 0.18p from 0.22p in 2023. Production
and development costs of £1.5m (2023: £1.7m) comprise the costs of
the Group's R&D facility ('QRF') in Essex, its operational
staff and consultants, and ongoing bioMSAR™ and MSAR®
development costs. These costs are largely related to fixed costs
with the reduction due to lower bioMSAR™ development and testing
costs.
Administration expenses of £1.3m
(2023: £1.3m), comprise the Group's corporate staff and directors'
costs, professional advisor fees, PR/IR costs and head office
costs.
At 30 June 2024, the Group had total
assets of £6.7m (2023: £5.3m). The most significant balances were
cash of £3.0m (2023: £1.3m), intangible assets of £2.9m (2023:
£2.9m), and property, plant and equipment of £0.4m (2023:
£0.4m). The Group has tax losses arising in
the UK of approximately £64.7m (2023: £62.1m) that are potentially
available to be carried forward against any future
profits.
Andy Morrison
Non-executive Chair
27 September 2024
Chief Executive's Statement
Addressing the Energy Transition Challenge
The shipping sector is responsible
for roughly 3% of global GHG emissions and is therefore under
increasing pressure from regulators and customers to decarbonise.
The sector is now in the midst of great transformation, with
numerous alternative fuel sources already in use or proposed as
longer-term options. Each solution has its benefits and drawbacks,
with some requiring entirely new vessels to be built (in the case
of future fuels, such as liquified natural gas 'LNG' or methanol).
Some require expensive retrofitting of existing vessels with them
removed from active service for long periods of time, and some
posing significant safety and logistical challenges (ammonia,
nuclear).
Quadrise offers a solution for
shipping operators to meet their decarbonisation targets whilst
continuing to use their existing fleet with minimal capital
investment, thus extending the life of vessels and reducing both
fuel costs and emissions.
Revolutionary Quadrise Technology and Synthetic
Fuels
Our patented Quadrise blending
technology and fuels offer a practical and cost-effective path for
operators in the marine sector, as well as those in the industrial
and power sectors, to decarbonise, reduce energy costs and lower
associated emissions safely. Our unique technology can blend a wide
range of oil and water-soluble components to produce highly stable
MSAR® and bioMSAR™ emulsion fuels.
·
MSAR® is a synthetic fuel oil that is
supplied at lower energy cost. When compared to conventional fuel
oil, it reduces carbon dioxide ("CO2") emissions by up
to 10% in diesel engines by lowering fuel consumption (further
lowering costs) as well as lowering emissions of nitrogen oxides
and particulates. It is an oil-in-water emulsion, made by blending
oil refinery residue streams (or heavy bitumen or crude oils) with
water and specialised additives in a proprietary production
process.
·
bioMSAR™ incorporates renewable glycerine to
produce a synthetic biofuel that offers all the benefits of
MSAR® but with 20-30% less CO2 than fuel oil
and cost savings of approximately 10% compared to standard
biofuels. bioMSAR™ outperforms LNG and marine biofuel blends in
terms of lower CO2 emissions per unit of energy "well to
wake". Other benefits include improved safety during use, and
improved dispersibility and biodegradability in the unlikely event
of a spill.
Immediately Deployable, Future-Proof
Solutions
Our modular systems are commercially
proven and ready for rapid deployment at scale to the downstream,
power, industrial and global shipping sectors. The economic and
environmental savings generated deliver immediate benefits to users
as the world transitions towards net-zero fuel solutions at a pace
that is still uncertain and governed by regulation, adoption and
customer choice.
A Quadrise blending module is a low
capital technology that can manufacture MSAR® or
bioMSAR™ interchangeably, providing a lower-cost environmental
solution to conventional liquid fuels today whilst offering the
opportunity to transition to sustainable biofuels based on consumer
choice.
With one eye on the future, we have
an established R&D strategy that leverages our innovative,
adaptable technology and our commercial application experience. We
are collaborating with fellow innovators in the sustainable fuel
sector to expand our portfolio of lower-cost, renewable, and
abundant biofuel components.
Supply partners and collaborators
include Cargill NV (who supply sustainable biofuels, bio-oils and
glycerine), Vertoro BV (producers of a crude sugar oil "CSO™" that
we have successfully tested in diesel engines ) and BTG Bioliquids
BV (using their 'FPBO' biofuel products and sugar components
produced by fast pyrolysis) derived from sustainable biomass such
as agricultural and sawmill waste.
Our Quadrise Research Facility (QRF)
in Essex is a valuable resource for "proof-of-concept" testing of a
range of second-generation biofuel components offered by an
increasing number of potential suppliers interested in the bioMSAR™
solution to ultimately provide a net-zero solution for
hard-to-abate energy sectors.
Quadrise is the transition
technology partner that creates low-carbon, low-emission and
low-cost energy solutions. These solutions are more accessible than
future fuel alternatives and are compatible and retrofit-ready with
existing fleets, enhancing profitability, extending asset life, and
reducing emissions and GHG impacts.
Key
project status
Decarbonisation of Global
Shipping: MSC
Our flagship project with MSC
Shipmanagement, which operates the largest shipping container fleet
in the world, will demonstrate that Quadrise can play an important
role in the decarbonisation of shipping. The project covers trials
of MSAR® and bioMSAR™ fuels on board an operationally
active MSC vessel (the MSC Leandra V) ahead of commercial supply to
MSC upon successful trial completion.
In preparation for the MSC vessel
trial fuel supply, a Collaboration Agreement between Quadrise,
Cargill NV and MAC² Solutions NV was signed in February 2024. The
fuels for the trial will be produced using a Quadrise
MSAR® Manufacturing Unit ('MMU') and associated
equipment, which will be installed at the MAC² bunker facility in
Antwerp, Belgium. MSAR® and bioMSAR™ fuels will then be
produced using fuel oil and glycerine feedstocks supplied by
Cargill, who will also be responsible for bunkering operations to
supply the fuels to the MSC vessel. Planning for success, during
the LONO trial the parties expect to conclude a Commercial Supply
Agreement and secure bioMSAR™ bunker supply operations to the
marine sector by Cargill from MAC2 facilities in Antwerp
and Bruges on a permanent basis.
Following signature of the
Collaboration Agreement, Quadrise have completed the purchase of
critical-path trial equipment, including centrifuges and fuel
filters, whilst MAC2 have obtained the permits required
for the trial to proceed and have prepared the groundworks in
readiness for installation of Quadrise equipment.
The signature of the binding
agreement between Quadrise, MSC and Cargill has unfortunately taken
longer than envisaged, however, the parties are collaborating
positively to finalise this as soon as possible. The binding 3-way
agreement establishes heads-of-terms covering associated binding
bilateral agreements for toll manufacture, terminal services and
fuel supply, which will also follow during Q4 2024, and in parallel
trial preparations will commence as soon as the initial binding
agreement has been signed.
The trial will comprise initial
Proof of Concept ("POC") tests of MSAR® and bioMSAR™,
followed by 4,000 hours of operation on bioMSAR™ to obtain a Letter
of No Objection ("LONO") from the engine manufacturer, Wärtsilä.
The bioMSAR™ LONO trial is expected to conclude 6-8 months
following completion of the 2-month long POC tests. Approximately
10,000-12,000 tonnes of Quadrise fuels will be consumed over the
period. In preparation for the vessel trial a Hazard Identification
Study ("HAZID") was completed in September 2023 by Lloyds Register
as Class Society for the vessel. This involved experts from
MSC, Wärtsilä and Quadrise. Installation and commissioning of the
Quadrise trial equipment at MAC² is currently expected in Q4 2024,
ahead of fuel production commencing in early Q1
2025.
In addition to the MSC project, the
Company continues to develop strategic options and partnerships
with other shipping companies with the intention of accelerating
the commercialisation of both bioMSAR™ and MSAR® for
marine applications.
In line with our strategy to
decarbonise shipping, we are exploring opportunities in parallel to
supply MSAR® to MSC and others from North-West Europe,
the Mediterranean, North and Central America, and Southeast Asia to
support demand from the major marine bunker hubs and our other
clients.
Morocco:
OCP
The Company's key project with OCP
S.A. ('OCP'), a major international manufacturing and mining group
in Morocco, will at the same time stimulate supply of
MSAR® in the Mediterranean, a significant region for
maritime trade and bunkering due to its strategic
location.
In November 2023, Quadrise
successfully completed an industrial demonstration test of
MSAR® and bioMSAR™ at one of OCP's major industrial
sites in Morocco. The industrial unit tested was successfully
operated at varying loads of up to 100%, equivalent to 33MW of
energy that is supplied by a single burner. This is similar to the
energy consumption of a medium-sized container ship. This was the
first demonstration of bioMSAR™ in a commercial
application.
Under the Commercial Framework
Agreement ("CFA") signed in May 2024, a further paid-for trial was
agreed to expand the opportunity for both OCP and Quadrise, as well
as the process to progress commercial supply discussions for
MSAR®. The Company is thus currently finalising
preparations for a 30-day MSAR® trial at OCP's Jorf
Lasfar site ('Jorf') whilst also completing the engineering studies
necessary for commercial MSAR® use there. The
MSAR® equipment has been shipped to site to prepare for
the trial, which is scheduled to be completed in Q4
2024.
Quadrise has opened discussions with
candidate suppliers for long-term commercial MSAR®
production and delivery with a view to signing a term supply
agreement following successful completion of the Jorf
trial.
USA lower carbon fuels:
Valkor, Utah
The project with Valkor targets the
supply of very-low sulphur MSAR® and bioMSAR™ from
extra-heavy oil deposits directly into the marine and power
sectors. Quadrise technology will be installed at a central
processing facility at Valkor's Asphalt Ridge site in Utah, USA,
with the finished products then transported to major ports and
power stations. The available hydrocarbon reserves at Asphalt Ridge
comprise billions of barrels, with Valkor having sizeable interests
in several projects at this location. Unitisation and enhanced oil
recovery plans for the project were approved by State of Utah's
Board of Oil, Gas and Mining in July 2024.
The properties of Valkor's heavy oil
will enable MSAR® or bioMSAR™ derived from it to comply
with International Maritime Organisation regulations without the
need for costly and carbon-intensive oil refining, providing highly
marketable lower carbon, ultra-low sulphur emulsion
fuel.
In June 2023, Quadrise signed a Site
License and Supply Agreement ("SLS") with Valkor, under which the
Company granted Valkor the exclusive right and license to use its
technology at the planned central processing facility and to market
the finished products on a non-exclusive basis. Under the SLS,
Valkor will pay Quadrise a US$1.0 million license fee subject to
receipt by Valkor of project financing of at least US$15 million.
Valkor will pay Quadrise a further US$0.5 million upon receipt of
an MMU and a quarterly retainer of US$75,000 for engineering,
project development and support services for at least two
years.
Following successful pilot drilling
in Q2 2024, oil production testing of the downhole electrical
heating system commenced in July 2024 managed by Valkor. Oil
production from the first well was confirmed in September
2024. Representative production barrels of 6-8°API
extra-heavy sweet oil were prepared by Valkor in September, samples
of which are being shipped to Quadrise for analysis and formulation
optimisation testing at QRF. Commercial marketing to the marine,
utilities and industrial sectors is expected to commence as soon as
testing is completed by Quadrise. Initial marketing targets will
include local power producers and marine vessels bunkering on the
US West Coast. Valkor expect to drill additional oil wells by 2024
year-end to increase oil production to 500-800 barrels per day and
are increasingly confident about their efforts to secure project
financing.
Other Projects
During the period, Quadrise
commenced discussions with an oil refinery in Southeast Asia that
is interested in conducting a trial using MSAR®
technology for internal thermal applications, as a precursor to
commercial supply of a "Mini-MMU" producing 5 tons per hour. The
refinery is situated near to bulk oil storage and offers potential
opportunities to supply Singapore, the world's largest bunker
hub.
The expansion of availability of
MSAR® and bioMSAR™ into other major marine hubs such as
the Panama Canal is seen by the Board as being vital to the future
scaling of the Company's business. In 2023, Quadrise signed a
Letter of Intent with Sparkle Power, a power generator in Panama
for a commercial test of MSAR® and bioMSAR™. During this
financial year, prolonged drought conditions in Panama reduced
hydroelectric power supply capacity and Sparkle Power were called
upon to provide additional emergency power. With no spare capacity
available, they were not able to progress trial preparations.
Environmental conditions have now improved, and discussions with
Sparkle have resumed.
Together with our local agents, we
also continue to explore other opportunities in the region to
create demand and stimulate supply in and around Panama and
Honduras, the latter being a large consumer of fuel oil for power
generation.
bioMSAR™: the transition solution for net-zero
energy
The Quadrise product development
roadmap is focused on providing low-carbon, low-emission and
low-cost solutions to address key transition challenges for
maritime decarbonisation and other market sectors that we
serve:
·
Supplying a drop-in biofuel solution (bioMSAR™)
rapidly, at commercial scale globally at terminals or on-board
vessels.
·
Ensuring the bioMSAR™ platform is sufficiently
adaptable to incorporate a range of sustainable biofuel
feedstocks.
·
Delivering a commercially viable 'bioMSAR™ Zero'
(labelled 'B100' - with 100% biogenic energy) solution before
2030.
Collaboration is key to this
initiative, and we are working with several like-minded strategic
partners to investigate lower cost, renewable and abundant biofuel
feedstocks for bioMSAR™. Work on this important programme during
the period has been very active:
bioMSAR™ incorporating biodiesel and bio-oil
byproducts
During the period, testing commenced
on blends of bioMSAR™ incorporating 'B30' biofuel, supplied by
major trading companies. B30 is a blend of 30% fatty acid methyl
esters (or 'FAME', which is also used in biodiesel) and 70% fuel
oil and is currently the most widely available marine biofuel.
Incorporation of B30 combined with glycerine further reduces the
fossil fuel content of our emulsion blends, providing an additional
potential pathway to bioMSAR™ Zero.
When compared to diesel, the
B30-based bioMSAR™ blends demonstrated:
·
Over 38% well-to-wake CO2 reductions
based on the carbon intensity of the components.
·
Enhanced diesel engine efficiency of 3-7% with a
corresponding reduction in fuel consumption (further reducing
overall CO2 emissions to 45%).
·
Reductions in NOx emissions of 43%-59%.
During Q3 2024, testing continued,
incorporating higher concentrations of waste-based bio-oils with
the intention to produce our first prototypes of 'B100' bioMSAR™
Zero, a 100% sustainable biofuel. Following successful pilot
testing at QRF, engine testing is now scheduled at Aquafuel
Research Limited, where our 40kW Cummins diesel engine is situated.
Quadrise is therefore on track to demonstrate a commercial bioMSAR™
Zero product well ahead of the Company's 2030 target.
bioMSAR™ incorporating sustainable biomass-derived sugars and
alcohols
Large-scale supply and wide
availability of fuel options are seen as key customer requirements
for scale-up into marine and industrial applications. The ability
to use water-soluble biomass sugars within the Company's unique
oil-in-water emulsion fuels opens access to abundant bio-energy
waste resources, presenting the Company with a significant
opportunity.
In December 2023, a bioMSAR™ blend
incorporating crude sugar oils ("CSO™") provided by Vertoro BV was
successfully tested on the Company's Cummins engine. This testing
showed reductions of up to 25% in CO2 emissions, engine
efficiency improvements of 6-7% (taking total CO2
reductions to >30%) and reductions in NOx of around 30% compared
with diesel.
In May 2024 Vertoro announced a
partnership with Force Motor Yachts to design and supply a luxury
yacht that will run on bioMSAR™ Zero incorporating CSO™. This
initiative was formally launched at the Cannes Yacht Show in
September 2024. The new Force yacht provides a floating laboratory
and validation unit to accelerate access to Quadrise bioMSAR™ Zero
and Blend-on-Board technologies to lower costs and
emissions.
Work has also progressed during the
year with BTG Bioliquids BV ("BTL"), whose technology produces
pyrolysis sugars derived from biomass. BTL and Quadrise are working
with prospective partners who can use BTL's technology to supply
sugars for incorporation into bioMSAR™ at commercial scale.
Following successful pilot testing at QRF on bioMSAR™ incorporating
around 20% BTL pyrolysis sugars, engine testing is now scheduled
with results expected early Q4 2024.
Outlook
To paraphrase a recent report by
Lloyd's Register "The challenge
of maritime decarbonisation is not that it is happening, but that
it needs to happen so quickly."
Energy economics, environmental
considerations and emissions regulations are increasingly driving
the business case for MSAR® and bioMSAR™ technology.
Quadrise intends to make a significant contribution to the
decarbonisation of shipping through the coming year with the
signature of further license agreements and completion of
commercial-scale trials, leading to supply contracts and commercial
revenues from MSAR® and bioMSAR™ during the next 12
months.
Green fuel choices for the marine
and industrial markets that Quadrise serves are still far off, and
e-fuel availability at a competitive price remains a problem. This
has led some proponents of future fuels to hedge their bets with
new ship orders for conventional fuels. Those taking delivery of
new "dual-fuel" liquified natural gas (LNG) vessels are complaining
about limited fuel availability, with 80% still running on marine
fuel oil or biofuels. As conventional bio and renewable diesel
fuels face growing demand from other sectors, the need for
lower-cost and more widely available biofuels is likely to
rise.
Market and regulatory trends are set
to create an increasingly favourable environment for the Company to
advance its business. The implementation of new environmental
regulations, particularly in Europe, such as the EU ETS and
'Fit-for-55' are expected to significantly boost biofuel use and
technology investment, especially in the shipping sector. As
conventional biofuels like biodiesel and renewable diesel,
currently used in shipping, face growing demand from other sectors,
the need for lower-cost and widely available non-conventional
biofuels is likely to rise. These regulations, along with subsidies
for renewable waste-based biofuel feedstocks such as glycerine,
should enhance the attractiveness of bioMSAR™ for end-users. With
strong market conditions, the Company is well-positioned to
progress through commercial trials and gain further traction with
key clients.
The focus of Quadrise on the
decarbonisation of shipping and other sectors is an important
statement of intent. License agreements and commercial-scale trials
are designed to lead to supply contracts and commercial revenues
from MSAR® and bioMSAR™. Looking ahead, our continued
development of bioMSAR™ and net-zero solutions opens exciting
opportunities to deploy our unique proven emulsion technology,
helping our partners and clients to deliver a cleaner future for us
all.
Quadrise has a small, highly
motivated and capable team and our continued progress is only
possible through the significant contribution of everyone working
within the business and our shareholders for their loyal support.
We are very aware that project delays outside of our control have
disrupted our planned commercial progress this year, but we are
doing all that we can to expedite successful outcomes in multiple
continents and applications that should benefit us all.
Jason Miles
Chief Executive Officer
27 September 2024
Strategic Report
For
the year ended 30 June 2024
Principal Activity
The principal activity of the
Company is to develop markets for its proprietary emulsion
fuels, MSAR® and bioMSAR™ as low-cost, more environmentally friendly
substitutes for conventional heavy fuel oil ("HFO") and biofuels
for use in large marine diesel engines, power generation plants and
industrial applications.
Business Review and Future Developments
A full review of the Group's
activities during the year, recent events and future developments
is contained in the Chairman and CEO Statements.
Key
Performance Indicators
The Group's key performance
indicators are:
·
Performance against its annual plan, including
project timetables established with partners and clients,
and
·
Financial performance and position against the
approved budgets and cashflow forecasts.
The Board regularly reviews the
Group's progress against the key performance indicators above, with
a review held at least monthly with Non-Executive Directors. The
commercial performance of the Company and each of the Company's key
projects and business development opportunities are discussed at
length in the Chairman and CEO Statements.
Each year, a detailed two-year
budget and cash forecast is prepared by the Executive team and
following a comprehensive review process, is then approved by the
Board. Performance against budget and updated cash projections are
included within the monthly management accounts issued to and
reviewed by the Board.
For the year ended 30 June 2024,
progress against the Group's business model was slower than
anticipated, with delays to key projects as discussed in the CEO
statement. The financial performance of the Group was ahead of
budget due to lower than forecast expenditure on operations, staff
and consulting costs and net project expenditure.
Going Concern
The Group had a cash balance of
£3.0m as of 30 June 2024. Based on the latest
Company forecasts which assume the anticipated and important
receipt of an aggregate of US$1.5m from Valkor as described above,
these funds are expected to be sufficient to reach forecast
commercial revenues and cover net project expenditure and fixed
costs up to the end of June 2025. Additional funding will be
required beyond this point to bridge the gap to the generation of
sustainable positive cashflows, which are currently planned to
commence in H1 2026. The Directors have determined that the
continuation of the Group as a going concern will be dependent upon
successfully raising sufficient funds in the future to bridge this
gap and the prior receipt of the Valkor income. The Directors have
a reasonable expectation that such funds will be raised, although
no binding funding agreements are in place at the date of this
report and have therefore determined that it is appropriate to
prepare the financial statements on a going concern basis. However,
in the absence of additional funding being in place at the date of
this report, these conditions indicate the existence of a material
uncertainty. This may cast significant doubt on the Company's
ability to continue as a going concern and, therefore, that it may
be unable to realise its assets and discharge its liabilities in
the normal course of business. For further details behind the
judgments and estimations used by the Directors in reaching this
determination, refer to note 2.4.
Longer term viability statement
In reaching its conclusion on the
going concern assessment and longer-term viability of the Group,
the Board reviewed the Group's three-year cash flow forecasts which
cover the period to revenue generation and positive cashflow. This
period is applicable because it extends to the point at which the
Group is forecast to be generating sustainable positive cashflows.
The Board reviewed the underlying assumptions in this cashflow,
together with sensitivity analysis performed on these projections.
The Board believes these forecasts are based on a prudent
assessment of the Group's prospects and target markets, taking
account of reasonably possible scenarios given current market and
economic conditions. The risks outlined below have been considered
by the Board in their determination of longer-term viability, most
significantly 'Delay in commercialisation of MSAR® and funding risks' and 'No profit to date'.
In its sensitivity analysis and
review of underlying assumptions, which cover these risks, the
Board looked at delays in project timelines or that certain
projects might not be realised. The impact on the Company's
longer-term viability is that the timing and level of funds
required to take the Group to the point of sustainable positive
cashflows is then affected. However, the Board consider that the
Group remains viable in the longer term under the sensitivities
modelled.
The Board therefore has a reasonable
expectation that the Group will be able to continue in operation
and meet its liabilities as they fall due over the period of their
assessment, provided it is in receipt of the Valkor income and is
able to raise the funding required as outlined in the Going Concern
note above.
Climate Change
As discussed in both the Chairman's
and CEO's statements, our bioMSAR™ technology offers an alternative
to HFO with over 25% lower CO2 emissions. The Directors
believe that the growing global emphasis on the COP 26 Goals,
specifically the goal of transition to global net-zero carbon by
2050, present Quadrise with increasing opportunities to assist
marine, power and industrial clients in obtaining a cost-effective
solution to lowering their carbon emissions. Government actions to
reduce climate change therefore provide opportunities to Quadrise,
but the Board acknowledges that the Company may also be presented
with additional risks due to these actions.
Risks, including those introduced by
climate change and governmental actions to reduce climate change,
are discussed in the next section.
Principal Business Risks
Each year in the second quarter, the
Audit Committee assists the Executive Team in a structured
zero-based re-assessment of the Company's principal and emerging
risks. The review considers each operational sector and
organisational level including the Company's research and
development facility, QRF, and risks are then triaged for the
Company as a whole. The risk level is determined by its
probability, its potential impact on the Company, and whether these
factors have increased or decreased over the last 12 months. A
summary of "Principal Risks and Uncertainties" is reviewed at a
Board meeting. Subsequently a Risk Mitigation Strategy and Action
Plan is incorporated into the annual Business Planning exercise
conducted in June each year.
The principal risks identified
during this exercise, ranked in order of the likelihood of
occurrence, are set out below. These may not include all the risk
factors that could affect future results. Actual results could
differ materially from those anticipated because of these and
various other factors, and those set forth in the Group's other
periodic and current reports filed with the authorities from time
to time.
Receipt of funds from
Valkor
The Company's cashflow forecasts
assume the receipt of an aggregate of
US$1.5m (approx. £1.2m) of revenues from Valkor, which, together
with the £3.0m cash balance as at 30 June 2024 is
expected to be sufficient to reach forecast
commercial revenues and cover net project expenditure and fixed
costs up to the end of June 2025. At the date of this report, there
remains a risk that the $1.5m from Valkor is either not received or
is significantly delayed, in which event the Company's ability to
progress its projects will be at risk without further funding. The
Group mitigates this risk by maintaining strong control over its
pre-revenue expenditure, as well as by actively evaluating
strategic initiatives that would de-risk and/or facilitate the
delivery of the Group's key objectives.
Market scope and
risk
Faced with pressure to move away
from hydrocarbons, the Group still needs to progress its
MSAR® and bioMSAR™ endeavours into a volume business. The Group
addresses this challenge by continuing to promote the immediate and
practical environmental contribution of
MSAR® and bioMSAR™ to the shipping industry. The Group further
mitigates this risk by promoting the applicability of Quadrise
technology to other sectors such as in the power generation and
industrial sectors discussed in the CEO's Statement. The
marketability of our technology and the fuels produced is affected by the
variability of price spreads between light and heavy oils, the
relative cost of biofuel components, and the relative
competitiveness of oil, gas, biofuel and coal prices both for
prompt and future delivery and other factors beyond the control of
the Group.
Commercial
return
The Group has made considerable
progress in its rapid development and enhancement of bioMSAR™ to
meet the requirement for cleaner biofuels, whilst continuing to
advance commercial opportunities for MSAR® and reduce its treat costs in the face of reductions to fuel oil-gasoil
spreads in the future. During the commercial roll-out of bioMSAR™
there remain the considerable challenges of testing, feedstock
availability (see below), biofuel treatment options, formulation
optimisation and commercial demand still to overcome. There is a
risk the Group will
not achieve a commercial return due to major unanticipated change
in a key variable or, more likely, the aggregate impact of changes
to several variables which results in sustained depressed
margins.
The competitive position could be
affected by government regulations concerning taxation, duties,
specifications, importation and exportation of hydrocarbon fuels
and environmental aspects. Freight costs contribute substantially
to the final cost of supplied products and a major change in the
cost of bulk liquid freight markets could have an adverse effect on
the economics of the fuels business. The Group would mitigate this
risk through establishing appropriate flexibilities in the
contractual framework, offtake arrangements and price risk
management through hedging.
Feedstock sourcing
- MSAR®
The IMO2020 regulation designed to
motivate the use of very low sulphur fuel oils has negatively
impacted high sulphur residue supply, due to lack of alternative
markets. There is a risk that appropriately located high sulphur
residues cannot be sourced. The Group mitigates this risk by
utilising its deep understanding of the global refining industry,
targeting qualifying suppliers matched to prospective major
consumers. There are economic and other advantages to refiners in
running a proportion of high sulphur crude oils and the Group
believes that the emergence of an MSAR® commercial business would
motivate candidate feedstock suppliers to expedite high sulphur
residue supply.
Feedstock sourcing
- bioMSAR™
Sufficient quantities have been
identified for immediate trial purposes, but the volumes and
quality of renewable glycerine required for a substantial
commercial marine or industrial bioMSAR™ contract are beyond those
readily accessible. To mitigate this the Company is rapidly
increasing its knowledge of current and potential glycerine sources
and contracting with suppliers such as Cargill NV. Clearly a
commercial contract would again stimulate this market and thus
expedite feedstock supply. The Company is researching other
renewable feedstocks that could be utilised together with, or
instead of glycerine, such as Vertoro's CSO™ and BTL's pyrolysis
sugar biofuels from sustainable biomass.
Delay in
commercialisation and funding
risks
There is a risk that the
commercialisation of MSAR® and bioMSAR™ could be delayed
further, or unforeseen technical and/or commercial challenges
arise. This could mean that the Group may ultimately need to raise
further equity funds to remain operational. Depending on market
conditions and investor sentiment, there is a risk that the Group
may be unable to raise the required funds when necessary. The Group
mitigates this risk by maintaining strong control over its
pre-revenue expenditure, keeping up the momentum on its key
projects and maintaining regular contact with the financial markets
and investor community.
Technological
risk
There is a risk firstly that the
markets for MSAR®
and bioMSAR™ fuels adopt alternative fuels, making
these technologies redundant or secondly that the technology used
for their production may not be adequately robust for all
applications. This is in respect of the character and nature of the
feedstock and the parameters of transportation and storage
pertaining to a specific project. This risk may jeopardise the
early commercialisation of the technology and subsequent
implementation of projects; or give rise to significant liabilities
arising from defective fuel during plant operations. The Group
mitigates this risk by ensuring that its highly experienced key
personnel are closely involved with all areas of
MSAR® and
bioMSAR™ formulation and manufacture, and that the fuel is
thoroughly tested before being put into operational use.
Competition
risks
There is a risk that new competition
could emerge with similar technologies sufficiently differentiated
to challenge the Company's process. Were such competition to
emerge, this could result, over time, in further price competition
and pressure on margins beyond that assumed in the
Group's business planning.
This risk is mitigated by the limited global pool of expertise in
the emulsion fuel market combined with an enhanced R&D
programme aimed at optimising cost and performance and protection
of intellectual property. The Group also makes best use of scarce
expertise by developing close relationships with strategic
counterparties such as Nouryon while ensuring that key employees
are suitably incentivised.
Environment, Social and
Governance risks (ESG)
Quadrise is committed to providing
safer, cleaner and more affordable energy. By leveraging our
extensive RDI capabilities, and through continuous improvement
processes, Quadrise aims to be carbon-neutral by 2030. Furthermore,
high standards of corporate governance have always been a strength
and this places the Company in the top tier of AIM companies. We
maintain this commitment by adopting the highest disclosure
standards of the
UK Corporate Governance Code,
through the experience and commitment of our Non-executive
Directors and by following stringent Board policies and procedures.
The Company works to exceptional health, safety, environmental
protection and quality standards, with strong risk management
processes in place, all of which are supported by a first-class
team of professional advisors.
Other Business Risks
Dependence on key
personnel
The Group's business is dependent on
obtaining and retaining the services of key personnel of the
appropriate calibre as the business develops. The success of
the Group will
continue to be dependent on the expertise and experience of the
Directors and the management team, and the loss of personnel could
still have an adverse effect on the Group. The Group mitigates this risk
by ensuring that key personnel are suitably incentivised and
contractually bound.
Environmental
risks
The Group's operations are subject to the
environmental risks inherent in the oil processing and distribution
industry. The Group is subject to environmental laws and regulations in connection
with all its operations. Although the Group ensures compliance with all
applicable environmental laws and regulations, there are certain
risks inherent to its activities, such as accidental spills,
leakages or other circumstances that could expose the
Group to potential
liability.
Further, the Group may require approval from the
relevant authorities before it can undertake activities which are
likely to impact the environment. Failure to obtain such approvals
may prevent or delay such activities. The Group is unable to predict
definitively the effect of additional environmental laws and
regulations, which may be adopted in the future, including whether
any such laws or regulations would materially increase the
Group's cost of doing
business, or affect its operations in any area of its business. The
Group mitigates this risk by ensuring compliance with environmental
legislation in the jurisdictions in which it operates, and closely
monitoring any pending regulation or legislation to ensure
compliance.
No profit to
date
The Group has incurred aggregate losses
since its inception, and it is therefore not possible to evaluate
its prospects based on past performance. There can be no certainty
that the Group will
achieve or sustain profitability or achieve or sustain positive
cash flow from its activities.
Corporate and regulatory
formalities
The conduct of petroleum processing
and distribution requires compliance by the Group with numerous procedures and
formalities in many different national jurisdictions. It may not in
all cases be possible to comply with or obtain waivers of all such
formalities. Additionally, functioning as a publicly listed Company
requires compliance with the stock market regulations. The Group
mitigates this risk through commitment to a high standard of
corporate governance and 'fit for purpose' procedures, and by
maintaining and applying effective policies.
Economic, political,
judicial, administrative, taxation or other regulatory
factors
The Group may be adversely affected by
changes in economic, political, judicial, administrative, taxation
or other regulatory factors, in the areas in which the
Group operates and
conducts its principal activities. The Group has no direct exposure
to the Ukraine/Russia conflict and is not directly affected by the
ongoing conflict in the Middle East.
Andy Morrison
Non-executive Chair
27 September 2024
Consolidated
Statement of Comprehensive Income
For the year ended 30 June
2024
|
Notes
|
Year ended
30 June
2024
£'000s
|
Year
ended
30 June
2023 (Restated)
£'000s
|
Continuing operations
|
|
|
|
Revenue
|
|
-
|
-
|
Production and development
costs
|
|
(1,461)
|
(1,746)
|
Other administration
expenses
|
|
(1,336)
|
(1,334)
|
Share option charge
|
9
|
(260)
|
(178)
|
Warrant charge
|
10
|
(30)
|
-
|
Loss on disposal on fixed
assets
|
6
|
(3)
|
-
|
Foreign exchange loss
|
|
(2)
|
(6)
|
Operating loss
|
|
(3,092)
|
(3,264)
|
Finance costs
|
|
(9)
|
(8)
|
Finance income
|
|
32
|
12
|
Loss before tax
|
|
(3,069)
|
(3,260)
|
Taxation
|
4
|
209
|
154
|
Loss and total comprehensive loss for the
year
from continuing operations to owners of the
parent
|
(2,860)
|
(3,106)
|
|
|
|
|
Loss per share - pence
|
|
|
|
Basic
|
5
|
(0.18)
|
(0.22)
|
Diluted
|
5
|
(0.18)
|
(0.22)
|
Consolidated
Statement of Financial
Position
As at 30 June 2024
|
Notes
|
As at
30 June
2024
£'000s
|
As
at
30 June
2023 (Restated)
£'000s
|
As
at
1 July
2022 (Restated)
£'000s
|
Assets
|
|
|
|
|
Non-current assets
|
|
|
|
|
Property, plant and
equipment
|
6
|
388
|
374
|
398
|
Right of Use assets
|
|
159
|
283
|
85
|
Intangible assets
|
7
|
2,924
|
2,924
|
2,924
|
Non-current assets
|
|
3,471
|
3,581
|
3,407
|
Current assets
|
|
|
|
|
Cash and cash equivalents
|
|
3,048
|
1,342
|
4,423
|
Trade and other
receivables
|
|
118
|
89
|
103
|
Prepayments
|
|
91
|
119
|
177
|
Inventory
|
|
-
|
174
|
-
|
Current assets
|
|
3,257
|
1,724
|
4,703
|
TOTAL ASSETS
|
|
6,728
|
5,305
|
8,110
|
Equity and liabilities
|
|
|
|
|
Current liabilities
|
|
|
|
|
Trade and other payables
|
|
239
|
175
|
262
|
Lease liabilities due in less than
one year
|
|
102
|
108
|
26
|
Provision for lease
dilapidations
|
|
56
|
56
|
28
|
Current liabilities
|
|
397
|
339
|
316
|
|
|
|
|
|
Non-current liabilities
|
|
|
|
|
Lease liabilities due in greater
than one year
|
|
43
|
145
|
45
|
Non
Current liabilities
|
|
43
|
145
|
45
|
Equity attributable to owners of the parent
|
|
|
|
|
Issued share capital
|
|
17,648
|
14,069
|
14,069
|
Share premium
|
|
77,647
|
77,189
|
77,189
|
Merger reserve
|
|
3,777
|
3,777
|
3,777
|
Share option reserve
|
|
839
|
718
|
1,151
|
Warrant reserve
|
|
30
|
-
|
970
|
Reverse acquisition
reserve
|
|
522
|
522
|
522
|
Accumulated losses
|
|
(94,175)
|
(91,454)
|
(89,929)
|
Total shareholders' equity
|
|
6,288
|
4,821
|
7,749
|
TOTAL EQUITY AND LIABILITIES
|
|
6,728
|
5,305
|
8,110
|
Consolidated
Statement of Changes in Equity
For the year ended 30 June
2024
|
Issued capital
£'000s
|
Share premium
£'000s
|
Merger
reserve
£'000s
|
Share option
reserve
£'000s
|
Warrant reserve
£'000s
|
Reverse acquisition
reserve
£'000s
|
Accumulated
losses
£'000s
|
Total
£'000s
|
1
July 2022 (as reported)
|
14,069
|
77,189
|
3,777
|
1,151
|
970
|
522
|
(89,915)
|
7,763
|
Prior year adjustment
|
-
|
-
|
-
|
-
|
-
|
-
|
14
|
14
|
1
July 2022 (as restated)
|
14,069
|
77,189
|
3,777
|
1,151
|
970
|
522
|
(89,929)
|
7,749
|
Loss and total comprehensive loss
for the year (Restated)
|
-
|
-
|
-
|
-
|
-
|
-
|
(3,106)
|
(3,106)
|
Share option charge
|
-
|
-
|
-
|
178
|
-
|
-
|
-
|
178
|
Transfer of balances relating to
expired share options
|
-
|
-
|
-
|
(611)
|
-
|
-
|
611
|
-
|
Transfer of balances relating to
expired warrants
|
-
|
-
|
-
|
-
|
(970)
|
-
|
970
|
-
|
30
June 2023 (Restated)
|
14,069
|
77,189
|
3,777
|
718
|
-
|
522
|
(91,454)
|
4,821
|
1
July 2023
|
14,069
|
77,189
|
3,777
|
718
|
|
522
|
(91,454)
|
4,821
|
Loss and total comprehensive loss
for the year
|
-
|
-
|
-
|
-
|
-
|
-
|
(2,860)
|
(2,860)
|
New shares issued
|
3,579
|
895
|
|
|
|
|
|
4,474
|
Share issue costs
|
|
(437)
|
|
|
|
|
|
(437)
|
Share option charge
|
-
|
-
|
-
|
260
|
-
|
-
|
-
|
260
|
New warrants issued
|
-
|
-
|
-
|
-
|
30
|
-
|
-
|
30
|
Transfer of balances relating to
expired share options
|
-
|
-
|
-
|
(139)
|
-
|
-
|
139
|
-
|
30
June 2024
|
17,648
|
77,647
|
3,777
|
839
|
30
|
522
|
(94,175)
|
6,288
|
Consolidated
Statement of Cash Flows
For the year ended 30 June
2024
|
Notes
|
Year ended
30 June
2024
£'000s
|
Year
ended
30 June
2023 (Restated)
£'000s
|
Operating activities
|
|
|
|
Loss before tax from continuing
operations
|
|
(3,069)
|
(3,260)
|
Depreciation
|
6
|
205
|
197
|
Loss on disposal of fixed
assets
|
6
|
3
|
-
|
Finance costs paid
|
|
9
|
8
|
Finance income received
|
|
(32)
|
(12)
|
Share option charge
|
9
|
260
|
178
|
Warrant charge
|
|
30
|
-
|
Working capital adjustments
|
|
|
|
(Increase)/decrease in trade and
other receivables
|
|
(29)
|
14
|
Decrease in prepayments
|
|
28
|
58
|
Increase/(decrease) in trade and
other payables
|
|
64
|
(87)
|
Decrease/(increase) in
inventory
|
|
174
|
(174)
|
Net
cash used in Operating Activities
|
|
(2,357)
|
(3,078)
|
|
|
|
|
Finance costs paid
|
|
(9)
|
(8)
|
Taxation received
|
4
|
209
|
154
|
Net
cash outflow from operating activities
|
|
(2,157)
|
(2,932)
|
|
|
|
|
Investing activities
|
|
|
|
Finance income received
|
|
32
|
12
|
Purchase of property, plant and
equipment
|
6
|
(98)
|
(95)
|
Net
cash outflow from investing activities
|
|
(66)
|
(83)
|
|
|
|
|
Financing activities
|
|
|
|
Issue of Ordinary Share
Capital
|
|
4,474
|
-
|
Issue Costs
|
|
(437)
|
-
|
Payment of lease
liabilities
|
|
(108)
|
(66)
|
Net cash inflow/(outflow) from
financing activities
|
|
3,929
|
(66)
|
|
|
|
|
Net
decrease in cash and cash equivalents
|
|
1,706
|
(3,081)
|
Cash and cash equivalents at the
beginning of the year
|
|
1,342
|
4,423
|
Cash and cash equivalents at the end of the
year
|
|
3,048
|
1,342
|
Notes to the
Financial Information
1. Basis of
Preparation and Significant Accounting Policies
The financial information for the
year ended 30 June 2024 has been prepared in accordance
UK adopted international accounting
standards in conformity with the
requirements of the Companies Act 2006 and effective, or issued and
early adopted, as at the date of those statements.
The financial information contained
in this announcement does not constitute the Company's statutory
financial statements for the year ended 30 June 2024 but has been
extracted from them. These financial statements will be delivered
to the Registrar of Companies following the Company's Annual
General Meeting. The auditors have reported on these financial
statements, and their report was unqualified and did not contain
any statement under section 498(2) or (3) Companies Act
2006.
The financial information has been
prepared on the historical cost basis, except for the revaluation
of certain financial instruments. Details of the accounting
policies applied are set out in the financial statements for the
year ended 30 June 2024.
The financial information is
prepared in Pounds Sterling and all values are rounded to the
nearest thousand Pounds (£'000) except where otherwise
indicated.
Statutory financial statements for
the year ended 30 June 2023 were delivered to the Registrar of
Companies. The auditor's report on these financial statements was
unqualified and did not contain any statement under section 498(2)
or (3) Companies Act 2006.
The Directors do not propose a
dividend in respect of the year ended 30 June 2024 (2023:
nil).
This announcement was approved by
the Board on 27 September 2024.
2. Going Concern
As at 30 June 2024, the Group had a
cash balance of £3.0m. These funds are
expected to be sufficient to cover net project expenditure and
fixed costs up to 30 June 2025, beyond which additional funding
will be required to bridge the gap to the generation of sustainable
positive cashflows, with these now forecast to commence in H1
2026.
The basis for these expectations is
the Group business model, budget and business plan, and sensitivity
analysis, which have been reviewed and approved by the Board. The
model comprises the financial forecasts associated with each
project opportunity deemed to have a realistic chance of
progressing, with assumptions based on the latest market
information, agreements with counterparties and the status of
discussions.
The Directors carry out a detailed
risk assessment process each year, with key risks and mitigating
actions identified. Despite the ongoing global disruption caused by
Russia's invasion of Ukraine, the Directors note the positive and
sustained levels of engagement with partners, prospective clients
and project stakeholders worldwide during the year, with progress
continuing with regard to the Company's primary projects with MSC,
Valkor and OCP in Morocco. Existing and prospective commercial
partners make decisions based on long-term considerations, and the
Directors believe that the economic and environmental advantages
offered by MSAR® and bioMSAR™ are increasingly
attractive in periods of global uncertainty as counterparties look
to both generate savings and further improve their environmental
performance.
The Group's ability to reach
commercial revenues and sustainable positive cashflows will be
determined by the successful outcome of the forthcoming trials. The
Board are confident that the trials will be successful based upon
the following:
· Morocco: The forthcoming trial in Morocco involves the
combustion of MSAR® for thermal applications. This is a
similar application to that successfully trialled by Quadrise at
another OCP facility on a larger kiln installed with a 33MW burner
in 2023.
· MSC:
Once agreements are signed, the MSC trials will take place on the
same vessel used for the Maersk LONO trial (the MSC Leandra,
formerly the Seago Istanbul). In addition, the engine manufacturer
(Wartsila) and MSC are happy to proceed directly to on-vessel
trials, rather than commencing with an initial stationary engine
test, given their assessment of the low-risk nature of the
trial.
· Utah:
The Utah application is in the upstream sector, where similar
technology has been successfully demonstrated previously by
Quadrise Canada and in Venezuela with Orimulsion involving Quadrise
employees and consultants.
In addition, the positive results
generated by the Aquafuel testing on bioMSAR™ and the similar
properties of MSAR® and bioMSAR™ mean that trials
involving bioMSAR™ do not have a significantly higher risk of
failure than the MSAR® equivalents.
The Directors have reviewed both the
Group and Company's ability to operate as a going concern up to the
31 December 2026, and have determined that
the continuation of the Group and Company as a going concern will
be dependent upon successfully raising sufficient funds within 12
months of the financial statements sign off date to bridge the gap
between the exhaustion of existing funds and the generation of
sustainable positive cashflows. The Company is the 100% parent of
Quadrise International Limited ('QIL'), the subsidiary through
which the Group runs the operating and project activities discussed
above. The Directors have a reasonable expectation that with
positive trial results and ongoing progress to commercial revenues,
such funds will be raised, although no binding funding agreements
are in place at the date of this report, furthermore, notwithstanding the Board's confidence, there are currently no
binding agreements in place in respect of commercial
revenues.
The Directors have therefore
concluded that it is appropriate to prepare the Group and Company
financial statements on a going concern basis; however, in the
absence of additional funding being in place at the date of this
report, these conditions indicate the existence of a material
uncertainty which may cast significant doubt over the Group's
ability to continue as a going concern and, therefore, that it may
be unable to realise its assets and discharge its liabilities in
the normal course of business. The audit report draws attention to
going concern by way of a material uncertainty.
The financial statements do not
include the adjustments that would result if the Group and Company
were unable to continue as a going concern.
3. Segmental
Information
For the purpose of segmental
information, the reportable operating segment is determined to be
the business segment. The Group principally has one business
segment, the results of which are regularly reviewed by the Board.
This business segment is a business to produce emulsion fuel (or
supply the associated technology to third parties) as a low-cost
substitute for conventional heavy fuel oil ("HFO") for use in power
generation plants and industrial and marine diesel
engines.
Geographical Segments
The Group's only geographical
segment during the year was the UK.
4. Taxation
|
Year ended
30 June
2024
£'000s
|
Year
ended
30 June
2023
£'000s
|
UK corporation tax credit
|
(209)
|
(154)
|
Total
|
(209)
|
(154)
|
No liability in respect of
corporation tax arises as a result of trading losses.
Tax
Reconciliation
|
Year ended
30 June
2024
£'000s
|
Year
ended
30 June
2023 (Restated)
£'000s
|
Loss on continuing operations before
taxation
|
(3,069)
|
(3,260)
|
Loss on continuing operations before
taxation multiplied by
the UK corporation tax rate of 25%
(2023: 20.5%)
|
(767)
|
(668)
|
Effects of:
|
|
|
Non-deductible
expenditure
|
77
|
40
|
Super deduction
|
|
(3)
|
R&D tax credit
|
(209)
|
(154)
|
Tax losses carried
forward
|
690
|
631
|
Total taxation credit on loss from continuing
operations
|
(209)
|
(154)
|
At the Spring Budget 2021, the
government announced that the Corporation Tax rate would increase
from 19% to 25% from 1 April 2023. As such, a blended rate of 20.5%
has been applied to the previous financial year to account for the
change in Corporation tax as at 1 April 2023. The current year UK
corporation tax rate is 25%.
The Group has tax losses arising in
the UK of approximately £64.7m (2023:
£62.1m) that are available, under current
legislation, to be carried forward against future profits. However,
the ability to utilise the losses is restricted, being dependant on
the type of loss and when it arose. The use of losses under the UK
corporation tax regime was reformed from 1 April 2017 such that
different rules on the use of losses apply to losses arising
pre-April 2017 and post-April 2017. Pre-2017 trading losses can
only be deducted against profits of the same trade within the
company in which they arose, whereas the post-2017 trading losses
can be used more widely and are deductible against total profits of
the group.
Reconciliation of tax losses
|
Year ended
30 June
2024
£'000s
|
Year
ended
30 June
2023
£'000s
|
Trading losses
|
38,879
|
36,255
|
Non-trade deficits arising in
Intangible Assets within Quadrise
International Limited
|
25,758
|
25,758
|
Capital losses
|
89
|
89
|
Total
|
64,726
|
62,101
|
A deferred tax asset representing
these losses and other temporary differences at the statement of
financial position date of approximately £16.18m (2023: £15.53m)
has not been recognised as a result of existing uncertainties in
relation to its realisation.
5. Loss Per Share
The calculation of loss per share is
based on the following loss and number of shares:
|
Year ended
30 June
2024
|
Year
ended
30 June
2023 (Restated)
|
Loss for the year
(£'000s)
|
(2,860)
|
(3,106)
|
Weighted average number of
shares:
|
|
|
Basic
|
1,600,731,743
|
1,406,904,968
|
Diluted
|
1,600,731,743
|
1,406,904,968
|
|
|
|
Loss per share:
|
|
|
Basic
|
(0.18)p
|
(0.22)p
|
Diluted
|
(0.18)p
|
(0.22)p
|
Basic loss per share is calculated
by dividing the loss for the year from continuing operations of the
Group by the weighted average number of ordinary shares in issue
during the year.
For diluted loss per share, the
weighted average number of ordinary shares in issue is adjusted to
assume conversion of all potential dilutive options over ordinary
shares. Potential ordinary shares resulting from the exercise of
share options have an anti-dilutive effect due to the Group being
in a loss position. As a result, diluted loss per share is
disclosed as the same value as basic loss per share. The 18.3m
dilutive share options issued by the Company and which are
outstanding at year-end could potentially dilute earnings per share
in the future if exercised when the Group is in a profit-making
position.
6. Property, plant and
equipment
Consolidated
|
|
Leasehold
Improvements
|
Computer
Equipment
|
Software
|
Furniture and Office
Equipment
|
Plant and
machinery
|
Total
|
|
£'000s
|
£'000s
|
£'000s
|
£'000s
|
£'000s
|
£'000s
|
Cost
|
|
|
|
|
|
|
Opening balance - 1 July
2023
|
89
|
96
|
43
|
24
|
1,524
|
1,776
|
Additions
|
-
|
1
|
-
|
-
|
97
|
98
|
Disposals
|
-
|
-
|
(20)
|
-
|
(64)
|
(84)
|
Closing balance - 30 June 2024
|
89
|
97
|
23
|
24
|
1,557
|
1,790
|
|
|
|
|
|
|
|
Depreciation
|
|
|
|
|
|
|
Opening balance - 1 July
2023
|
(79)
|
(91)
|
(43)
|
(16)
|
(1,173)
|
(1,402)
|
Depreciation charge for the
year
|
(3)
|
(2)
|
-
|
(1)
|
(75)
|
(81)
|
Disposals
|
-
|
-
|
20
|
-
|
61
|
81
|
Closing balance - 30 June 2024
|
(82)
|
(93)
|
(23)
|
(17)
|
(1,187)
|
(1,402)
|
|
|
|
|
|
|
|
Net
book value at 30 June 2024
|
7
|
4
|
-
|
7
|
370
|
388
|
Company
|
|
Leasehold
Improvements
|
Computer
Equipment
|
Software
|
Furniture and Office
Equipment
|
Plant and
machinery
|
Total
|
|
£'000s
|
£'000s
|
£'000s
|
£'000s
|
£'000s
|
£'000s
|
Cost
|
|
|
|
|
|
|
Opening balance - 1 July
2023
|
-
|
69
|
44
|
24
|
-
|
137
|
Additions
|
-
|
-
|
-
|
-
|
-
|
-
|
Disposals
|
-
|
-
|
(20)
|
-
|
-
|
(20)
|
Closing balance - 30 June 2024
|
-
|
69
|
24
|
24
|
-
|
117
|
|
|
|
|
|
|
|
Depreciation
|
|
|
|
|
|
|
Opening balance - 1 July
2023
|
-
|
(66)
|
(44)
|
(16)
|
-
|
(126)
|
Depreciation charge for the
year
|
-
|
(1)
|
-
|
(1)
|
-
|
(2)
|
Disposals
|
-
|
-
|
20
|
-
|
-
|
20
|
Closing balance - 30 June 2024
|
-
|
(67)
|
(24)
|
(17)
|
-
|
(108)
|
|
|
|
|
|
|
|
Net
book value at 30 June 2024
|
-
|
2
|
-
|
7
|
-
|
9
|
7. Intangible Assets
Consolidated
|
QCC royalty
payments
|
MSAR® trade name
|
Technology and
know-how
|
Total
|
|
£'000s
|
£'000s
|
£'000s
|
£'000s
|
Cost
|
|
|
|
|
Balance as at 1 July 2023 and 30
June 2024
|
7,686
|
3,100
|
25,901
|
36,687
|
|
|
|
|
|
Amortisation and Impairment
|
|
|
|
|
Balance as at 1 July 2023 and 30
June 2024
|
(7,686)
|
(176)
|
(25,901)
|
(33,763)
|
|
|
|
|
|
Net
book value as at 30 June 2024
|
-
|
2,924
|
-
|
2,924
|
Cost
|
|
|
|
|
Balance as at 1 July 2022 and 30
June 2023
|
7,686
|
3,100
|
25,901
|
36,687
|
|
|
|
|
|
|
|
Amortisation and Impairment
|
|
|
|
|
|
Balance as at 1 July 2022 and 30
June 2023
|
(7,686)
|
(176)
|
(25,901)
|
(33,763)
|
|
|
|
|
|
|
|
Net
book value as at 30 June 2023
|
-
|
2,924
|
-
|
2,924
|
|
Intangible assets comprise
intellectual property with a cost of £36.7m, including assets of
finite and indefinite life. Quadrise Canada Corporation's ("QCC's)
royalty payments of £7.7m and the MSAR® trade name of £3.1m
are termed as assets having indefinite life as it is assessed that
there is no foreseeable limit to the period over which the assets
would be expected to generate net cash inflows for the Group, as
they arise from cashflows resulting from Quadrise and QCC gaining a
permanent market share. The assets with indefinite life are not
amortised, but the QCC royalty payments intangible asset became
fully impaired in 2012.
The remaining intangibles amounting
to £25.9m, primarily made up of technology and know-how, are
considered as finite assets and were amortised over 93 months,
being fully amortised in 2012. The Group does not have any
internally generated intangibles.
MSAR® trade name
intangible
asset
In accordance with IAS 36
"impairment of assets" and IAS 38 "intangible assets", a review of
impairment for indefinite life intangible assets is undertaken
annually or at any time an indicator of impairment is considered to
exist. The discount rate applied to calculate the present value is
for the cash generating unit ("CGU"). A CGU is the smallest
identifiable group of assets that generates cash inflows that are
largely independent of the cash inflows from other assets or groups
of assets. The recoverable amount of the CGU is assessed by
reference to the value in use ("VIU"), being the net present value
("NPV") of future cash flow expected to be generated by the asset,
and fair value less costs to sell ("FVLCS").
The recoverable amount of the MSAR®
trade name intangible asset has been determined using a VIU model.
The expected future cash flows utilised in the VIU model are
derived by quantifying the royalties that would result if the asset
was licensed from a third party in order to determine the income
stream directly attributable to the asset in isolation. The
royalties are based on a percentage of projected future revenues up
to 30 June 2034 with an assumed growth rate being used beyond that
date.
The key assumptions used in this
calculation are as follows:
|
2024
|
2023
|
Royalty rate (% of projected
revenue) 1
|
0.5%
|
0.5%
|
Discount rate
2
|
20%
|
20%
|
Revenues forecast up to
3
|
30 June 2034
|
30 June 2033
|
Growth rate beyond forecast period
4
|
0%
|
0%
|
1) The
royalty rate used upon initial recognition of this intangible asset
was 0.33% of revenues determined as part of a third-party
intangible asset valuation exercise. This was increased to 0.5% of
revenues from 2011 onwards to reflect the wider awareness of the
MSAR® trademark in the market.
2) The
discount rate of 20% has been determined by management as
conservative estimate based on the uncertainty inherent in the
revenue forecasts. Management estimates the
discount rates using pre-tax rates that reflect current market
assessments of the time value of money and risks specific to
expected future projects.
3)
The 2024 revenue forecast extends to 30 June 2034
which is considered to be a reasonable timeframe that
allows each project included within the forecast to
reach full maturity.
4)
No growth has been forecast beyond the forecast
period due to the uncertainty inherent in the revenue projections
beyond the stage of project maturity.
The revenue forecast is based on the
latest Company business model, which is regularly reviewed by
management. The basis for the inclusion of projects and the
estimation of growth rates, margins and
project lifespans within the business model is based on the latest
agreements with counterparties, commodity and chemical prices and
the most recent discussions with customers, suppliers and other
business partners.
The 'base-case' impairment
assessment based on the above inputs shows a recoverable amount for
the asset that is in excess of the net book value of asset and
therefore no impairment has been identified, with the VIU exceeding
the carrying value by £2.02m (the
'headroom').
Management have performed
sensitivity analyses whereby certain parameters were flexed
downwards by reasonable amounts and certain scenarios were modelled
for the CGU to assess whether the recoverable value would result in
an impairment charge. In isolation, none of
these scenarios would result in an impairment to the
MSAR® Trade Name intangible asset. However, a
combination of two or more of these scenarios could result in an
impairment charge, but management do not consider this
likely.
The following sensitivities were
applied:
Results of sensitivity analysis
Scenario
|
Resulting headroom (£'m)
|
Scenario which would reduce headroom to nil
|
Delayed revenues (1 year)
|
1.52
|
A 3 year delay to forecast
revenues.
|
Delayed revenues (2 years)
|
0.78
|
A 3 year delay to forecast
revenues.
|
Increase in discount rate to
25%
|
0.61
|
Increase in discount rate to
27.6%.
|
Removal of projects which generate
25% of forecast revenues
|
1.07
|
Removal of projects which generate
45% of revenues.
|
Finite company lifespan (to 30 June
2035).
|
0.88
|
Finite company lifespan (to 30 June
2033).
|
Amortisation of Intangible Assets
The Board has reviewed the
accounting policy for intangible assets and has amortised those
assets which have a finite life. All intangible assets with a
finite life were fully amortised as at 30 June 2024.
8. Investments
At the statement of financial
position date, the Group held a 20.44% share in the ordinary issued
capital of Quadrise Canada Corporation ("QCC"), a 3.75% share in
the ordinary issued capital of Paxton Corporation ("Paxton"), a
9.54% share in the ordinary issued capital of Optimal Resources
Inc. ("ORI") and a 16.86% share in the ordinary issued capital of
Porient Fuels Corporation ("Porient"), all of which are
incorporated in Canada.
QCC is independent of the Group and
is responsible for its own policy-making decisions. There have been
no material transactions between QCC and the Group during the
period or any interchange of managerial personnel. As a result, the
Directors do not consider that they have significant influence over
QCC and as such this investment is not accounted for as an
associate.
The Group has no immediate intention
to dispose of its investments unless a beneficial opportunity to
realise these investments arises.
Given that there is no active market
in the shares of any of above companies, the Directors have
determined the fair value of the unquoted securities at 30 June
2024. The shares in each of these companies were valued at CAD $nil
on 1 July 2022 due to their business models being highly uncertain,
with minimal possibility of any material value being recovered from
their asset base. During the year there has been no indication that
this situation has changed, therefore the Directors have determined
that the investments should continue to remain valued at CAD $nil
at 30 June 2024.
9. Share Options
Share option expense for the year
ended 30 June 2024 was £260k (2023: £178k).
Movement in the year:
The following table illustrates the
number and weighted average exercise prices ("WAEP") of, and
movements in, share options during the year:
|
Number
30 June
2024
|
WAEP
(pence)
30 June
2024
|
Number
30 June
2023
|
WAEP
(pence)
30 June
2023
|
|
|
|
|
|
Outstanding as at 1 July
|
35,763,811
|
4.39
|
21,385,343
|
9.00
|
Granted during the year
|
52,444,444
|
1.51
|
36,233,038
|
3.28
|
Expired during the year
|
(18,500,000)
|
3.60
|
(21,854,570)
|
7.07
|
Exercised during the year
|
-
|
-
|
-
|
-
|
Options outstanding as at 30 June
|
69,708,255
|
2.44
|
35,763,811
|
4.39
|
Exercisable as at 30 June
|
29,763,811
|
4.17
|
16,231,895
|
6.55
|
The weighted average remaining
contractual life of the 69.71 million options outstanding at the
statement of financial position date is 7.45 years (2023: 6.40
years). The weighted average share price during the year was 1.61p
(2023: 1.57p) per share.
The expected volatility of the
options reflects the assumption that historical volatility is
indicative of future trends, which may not necessarily be the
actual outcome. The expected life of the options is based on
historical data available at the time of the option issue and is
not necessarily indicative of future trends, which may not
necessarily be the actual outcome.
The Share Option Schemes are equity
settled plans, and fair value is measured at the grant date of the
option. Options issued under the Schemes vest over a
one-to-three-year period provided the recipient remains an employee
of the Group. Options also may be exercised within an agreed period
of an employee leaving the Group at the discretion of the
Board.
The Company issued 52.4 million
share options to directors and employees during the year (2023:
36.2 million). The fair value was calculated using the Black
Scholes option pricing model. The weighted average inputs were as
follows
|
|
|
2024
|
2023
|
Stock price:
|
|
|
1.18p
|
1.46p
|
Exercise Price
|
|
|
1.51p
|
3.28p
|
Interest Rate
|
|
|
5.25%
|
2.16%
|
Volatility
|
|
|
98.23%
|
104.85%
|
Expected term (years)
|
|
|
2.69
|
3.69
|
|
|
|
|
|
10. Warrants
Movement in the year:
The following table illustrates the
number and weighted average exercise prices ("WAEP") of, and
movements in, warrants during the year:
|
Number
30 June
2024
|
WAEP
(pence)
30 June
2024
|
Number
30 June
2023
|
WAEP
(pence)
30 June
2023
|
|
|
|
|
|
Outstanding as at 1 July
|
-
|
-
|
40,228,026
|
6.98
|
Granted during the year
|
3,600,000
|
1.45
|
-
|
-
|
Exercised during the year
|
-
|
-
|
-
|
-
|
Expired during the year
|
-
|
-
|
(40,228,026)
|
6.98
|
Warrants outstanding as at 30 June
|
3,600,000
|
1.45
|
-
|
-
|
Exercisable as at 30 June
|
3,600,000
|
1.45
|
-
|
-
|
The warrants are equity settled
warrants which vest immediately on grant date. Fair value is
measured at the grant date of the option using the Black Scholes
pricing model. The inputs into this model are: Stock price at the
date of grant, exercise price, interest rate, expected term and
expected volatility. The expected volatility of the warrants
reflects the assumption that historical volatility is indicative of
future trends, which may not necessarily be the actual outcome. The
expected life of the warrants is based on historical data available
at the time of the option issue and is not necessarily indicative
of future trends, which may not necessarily be the actual
outcome.
The weighted average inputs into the
Black Scholes option pricing model were as follows:
|
|
|
2024
|
2023
|
Stock price:
|
|
|
1.70p
|
-
|
Exercise Price
|
|
|
1.45p
|
-
|
Interest Rate
|
|
|
5.25%
|
-
|
Volatility
|
|
|
112.86%
|
-
|
Expected term (years)
|
|
|
1.0
|
-
|
As at 30 June 2024, the weighted
average remaining contractual life of the 3.6 million warrants
outstanding was 0.92 years. The weighted average share price during
the year was 1.61p (2023: 1.57p) per share. No warrants were
outstanding as at 30 June 2023. The warrant charge for the year
ended 30 June 2024 was £30k (2023: £nil).
11.
Prior year restatement
Under IFRS 16, the disclosures and
accounting treatment of leases required under this standard should
have been adopted for the year ended 30 June 2023. The comparative
figures for the year ended 30 June 2023 have been therefore been
restated to reflect the correct accounting treatment..
Each of the affected financial statement
line items for the prior periods has been restated as
follows:
Consolidated Statement of Comprehensive
Income
|
30 June 2023 £'000
|
Increase/(decrease)
|
30 June 2023 (Restated)
£'000
|
|
|
|
|
Production and development
cost
|
(1,741)
|
(5)
|
(1,746)
|
Other administrative
expenses
|
(1,331)
|
(3)
|
(1,334)
|
Finance costs
|
(4)
|
(4)
|
(8)
|
Loss before tax
|
(3,248)
|
(12)
|
(3,260)
|
Consolidated Statement of Financial Position
|
30 June 2023 £'000
|
Increase/(decrease)
|
30 June 2023 (Restated)
£'000
|
|
|
|
|
Right of use assets
|
-
|
283
|
283
|
Provision for lease
dilapidations
|
-
|
(56)
|
(56)
|
Lease liabilities due in less than
one year
|
-
|
(108)
|
(108)
|
Lease liabilities due in greater
than one year
|
-
|
(145)
|
(145)
|
Accumulated losses
|
(91,428)
|
(26)
|
(91,454)
|
Consolidated Statement of Changes in Equity
|
30 June 2023 £'000
|
Increase/(decrease)
|
30 June 2023 (Restated)
£'000
|
|
|
|
|
Accumulated losses as at 1 July
2022
|
(89,915)
|
(14)
|
(89,929)
|
Loss and total comprehensive loss
for the year
|
(3,094)
|
(12)
|
(3,106)
|
Consolidated Statement of Cash Flows
|
30 June 2023 £'000
|
Increase/(decrease)
|
30 June 2023 (Restated)
£'000
|
|
|
|
|
Loss before tax from continuing
operations
|
(3,248)
|
(12)
|
(3,260)
|
Depreciation
|
119
|
178
|
197
|
Finance costs paid
|
4
|
4
|
8
|
Payment of lease
liabilities
|
-
|
(66)
|
(66)
|
12. Related Party Transactions
There are no transactions with
Directors or other related parties during the period other than
their remuneration as disclosed in the Report of Directors'
Remuneration.
13.
Events After the end of the Reporting Period
Issuance of Share Options
Performance Options
On 1 August 2024, the Company
granted a total of 13,880,000 options (the 'Performance Options')
over new ordinary shares of 1p each in the Company executives and
employees of the Company in accordance with the provisions of the
Company's Enterprise Management Incentive Plan ("EMI Plan") and the
Company's Unapproved Share Option Plan 2016 ("2016 Plan"). The
issue of these options follows the lapsing in full of the
13,500,000 options issued by the Company on 3 August
2023 due to the specific performance conditions of those
options not having been met. 7,500,000 of the Performance Options
were granted to Jason Miles, Chief Executive Officer of the
Company.
The Performance Options have an
exercise price of 2.5p, and will vest as to 50% on the first
anniversary of grant and the remaining 50% shall vest on the second
anniversary of the date of grant. All vestings are subject to the
satisfaction of specific performance conditions prior to the first
anniversary of grant. The Performance Options issued under the EMI
Plan will be exercisable from vesting until the tenth anniversary
of the date of grant. The Performance Options issued under the 2016
Plan will be exercisable from vesting until the eighth anniversary
of the date of grant
Additional Options
On 1 August 2024 Quadrise also
granted 6,000,000 options over new ordinary shares of 1p each in
the Company to Non-Executive Directors of
the Company in accordance with the
provisions of the Company's Unapproved Share Option Plan 2016
("2016 Plan") in the amounts set out below
(the "Additional Options").
Director
|
Number of Additional
Options
|
Andrew Morrison
|
3,000,000
|
Laurie Mutch
|
1,500,000
|
Vicky Boiten-Lee
|
1,500,000
|
Total
|
6,000,000
|
The Additional Options have an
exercise price of 2.5p. There are no
performance conditions to the vesting of the Additional Options,
which will vest as to 50% on the first anniversary of grant and the
remaining 50% shall vest on the second anniversary of the date of
grant. The Additional Options will be exercisable from vesting
until the eighth anniversary of the date of grant.
Nominal Value Options
On 3 August 2024, the Company
granted a total of 4,195,804 nominal value options ('NVOs') over
new ordinary shares of 1p each in the Company to executives and
employees in accordance with the provisions of the EMI
Plan.
These Options have an exercise price
of 1p, and will vest after 12 months from the date of grant, with
vesting not subject to performance conditions. The NVOs will be
exercisable from vesting until the tenth anniversary of the date of
grant.
14.
Copies of the Annual Report and Notice of Annual General
Meeting
Copies of the annual report and of
the notice convening the Company's 2024 annual general meeting will
be available shortly from the Company's website at
www.quadrisefuels.com and from the Company's registered
office, Eastcastle House, 27-28 Eastcastle
Street, London, W1W 8DH.